Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Psychedelic Drugs Market from 2024 to 2025?

In recent times, the market size of psychedelic drugs has seen significant growth. The market, which was valued at $5.56 billion in 2024, is expected to expand to $6.39 billion in 2025, with a compound annual growth rate (CAGR) of 14.9%. This increase throughout the historical period can be credited to changes in regulatory frameworks, enhanced awareness of mental health and a shift in public opinion.

What Is the Projected Market Size of the Psychedelic Drugs Market?

The market size of psychedelic drugs is projected to witness fast-paced progression in the forthcoming years. By 2029, this market is estimated to reach a valuation of $11.93 billion, escalating at a compound annual growth rate (CAGR) of 16.9%. Factors contributing to growth within the forecast period include improvements in drug formulation, the enlargement of therapeutic uses, greater endorsement from the medical field, shifts in public policy, and reaction to the mental health crisis. Key trends throughout this period will revolve around raising public awareness and education, legal and regulatory shifts, the broadening of psychedelic compounds, and treatment approaches centered on the patient.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6345&type=smp

Who are the Major Competitors in the Psychedelic Drugs Market Outlook?

Major companies operating in the psychedelic drugs market include Atai Life Sciences, Cybin Inc., Mind Medicine Inc., Compass Pathways, Seelos Therapeutics, Numinus Wellness Inc., GH Research, Revive Therapeutics, Havn Life Sciences, PharmaTher Holdings, Field Trip Health, Small Pharma, Incannex Healthcare, Optimi Health, NeonMind Biosciences, Entheon Biomedical, Mydecine Innovations Group, Red Light Holland, Eleusis, MAPS Public Benefit Corporation, Beckley Psytech, Awakn Life Sciences, Psygen Industries, Enveric Biosciences, Filament Health, Tactogen, Bexson Biomedical, BetterLife Pharma, Clairvoyant Therapeutics, Universal Ibogaine

What Is Fueling Growth in the Psychedelic Drugs Market?

The rise in mental health disorders is predicted to spur the expansion of the psychedelic drugs industry. These health disorders involve changes in emotions, cognition, or behavior, including conditions like distress and post-traumatic stress disorder. Psychedelic medications, utilized for treating depression and post-traumatic stress disorder, can lessen mental illnesses with consistent use. For example, the National Centre for Social Research, an established UK social research institute, reported in November 2022 that the ratio of 17- to 19-year-olds suspected to have a mental disorder increased from 17.4% in 2021 to 25.7% in 2022. Therefore, the escalating rate of mental illness cases is acting as a catalyst for the growth of the psychedelic drugs industry.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6345&type=smp

Which Psychedelic Drugs Market Segments Are Growing the Fastest?

The psychedelic drugs market covered in this report is segmented –

1) By Type: Lysergic Acid Diethylamide (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia

2) By Disease Indication: Depression, PTSD

3) By Origin: Natural, Synthetic

4) By Application: Treatment-Resistant Depression, Opiate addiction, Post- Traumatic Stress Disorder, Narcolepsy, Panic Disorders

5) By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Lysergic Acid Diethylamide (LSD): LSD Tablets, LSD Liquid, LSD Blotters

2) By Ketamine: Ketamine Infusion, Ketamine Nasal Spray, Ketamine Injectable

3) By Phencyclidine (PCP): PCP Powder, PCP Tablets, PCP Liquid

4) By Gamma Hydroxybutyric Acid (GHB): GHB Liquid, GHB Powder, GHB Capsules

5) By Salvia: Salvia Extract, Salvia Dried Leaves, Salvia Tinctures

Which Industry Trends Are Shaping the Future of the Psychedelic Drugs Market?

Primary firms within the psychedelic drugs market are concentrating their efforts on pioneering items such as ketamine, with the aim of advancing treatment results for mental health conditions, increasing treatment availability for patients, and investigating new uses for psychedelic components in areas including depression, anxiety, PTSD, and substance use disorders. Ketamine, notable for its dissociative features, is a medical drug used as an anesthetic and painkiller. It is also being scrutinized for its fast-acting antidepressant effects in managing severe depression and PTSD. For instance, Husch Blackwell, a conventional company based in the U.S., rolled out the Psychedelics and Emerging Therapies Practice Group in March 2022. The group’s purpose is to support innovators in their research, development, and commercialization process regarding new psychedelic-based therapies. It consists of an interdisciplinary lawyers’ team proficient in navigating the intricate legal environment tied to these substances, typically classified as Schedule I controlled substances under U.S. federal law. This classification creates substantial regulatory obstacles capable of hampering research and development activities.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/psychedelic-drugs-global-market-report

Which Countries Are Leading the Psychedelic Drugs Market?

North America was the largest region in the psychedelic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6345

This Report Delivers Insight On:

1. How big is the psychedelic drugs market, and how is it changing globally?

2. Who are the major companies in the psychedelic drugs market, and how are they performing?

3. What are the key opportunities and risks in the psychedelic drugs market right now?

4. Which products or customer segments are growing the most in the psychedelic drugs market?

5. What factors are helping or slowing down the growth of the psychedelic drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model